| Literature DB >> 33294087 |
Hao-Yang Wan1, Su-Yi Li2, Wei Ji3, Bin Yu1, Nan Jiang1.
Abstract
Background: With continuous increase of the aging population, the number of geriatric patients with fragility hip fractures is rising sharply, and timely surgery remains the mainstay of treatment. However, adequate and effective pain control is the precondition of satisfactory efficacy. This systematic review aimed to summarize the use of fascia iliaca compartment block (FICB) as an analgesic strategy for perioperative pain management in geriatric patients with hip fractures.Entities:
Year: 2020 PMID: 33294087 PMCID: PMC7714603 DOI: 10.1155/2020/8503963
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
The modified Jadad scale with eight items.
| Item assessed | Response | Score |
|---|---|---|
| Was the study described as randomized? | Yes | +1 |
| No | 0 | |
| Was the method of randomization appropriate? | Yes | +1 |
| No | −1 | |
| Not described | 0 | |
| Was the study described as blinded? | Yes | +1 |
| No | 0 | |
| Was the method of blinding appropriate? | Yes | +1 |
| No | −1 | |
| Not described | 0 | |
| Was there a description of withdrawals and dropouts? | Yes | +1 |
| No | 0 | |
| Was there a clear description of the inclusion/exclusion criteria? | Yes | +1 |
| No | 0 | |
| Was the method used to assess adverse effects described? | Yes | +1 |
| No | 0 | |
| Was the method of statistical analysis described? | Yes | +1 |
| No | 0 |
Double-blind obtains 1 score; single-blind obtains 0.5 score.
Figure 1Preferred reporting items for systematic reviews and meta-analyses flow diagram.
Methodological assessment of the RCTs included.
| Study | Random description | Random method | Blinding description | Blinding method | Withdrawals/dropouts description | Inclusion/exclusion criteria | Adverse effects assessment | Statistical methods description | Total score |
|---|---|---|---|---|---|---|---|---|---|
| Foss et al. 2007 [ | Yes | Yes | Yes | ND | Yes | Yes | No | Yes | 6 |
| McRae et al.2015 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Wennberg et al. 2019 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Pasquier et al. 2019 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Godoy Monzón et al. 2010 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Ma et al. 2018 [ | Yes | Yes | Yes | ND | Yes | Yes | No | Yes | 5.5 |
| Newman et al. 2013 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Zhou et al. 2019 [ | Yes | Yes | Yes | Yes | No | Yes | No | Yes | 6 |
| Cooper et al. 2019 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | No | 6 |
| Reavley et al. 2015 [ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 7.5 |
| Aprato et al. 2018 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 6.5 |
| Wennberg et al. 2019 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Yun et al. 2009 [ | Yes | Yes | Yes | ND | No | Yes | No | Yes | 4.5 |
| Diakomi et al. 2014 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 6.5 |
| Madabushi et al. 2016 [ | Yes | Yes | Yes | Yes | No | Yes | No | Yes | 5.5 |
| Kacha et al. 2018 [ | Yes | Yes | Yes | ND | No | Yes | No | Yes | 5 |
| Temelkovska-Stevanovska et al. 2014 [ | Yes | ND | No | ND | No | Yes | No | Yes | 3 |
| Deniz et al. 2014 [ | Yes | ND | No | ND | Yes | Yes | No | Yes | 4 |
| Bang et al. 2016 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Mostafa et al. 2018 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Yamamoto et al. 2019 [ | Yes | Yes | No | ND | Yes | Yes | Yes | Yes | 6 |
| Thompson et al. 2020 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 6.5 |
| Schulte et al. 2020 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Diakomi et al. 2020 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Mouzopoulos et al. 2009 [ | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 6.5 |
| Nie et al. 2015 [ | Yes | Yes | No | ND | Yes | Yes | No | Yes | 5 |
| Hao et al. 2019 [ | Yes | Yes | Yes | ND | Yes | Yes | No | Yes | 5.5 |
ND: not described.
RCTs evaluating FICB in pain management in geriatric patients with hip fracture.
| Study | Country | Comparison and no. of the included patients | FICB strategy | Outcome parameters | Primary conclusions |
|---|---|---|---|---|---|
| Preoperative use | |||||
| Foss et al. 2007 [ | Denmark | FICB = 24 vs IM morphine = 24 | 40 mL 1.0% mepivacaine | VRS (rest/movement), total morphine consumption | FICB provided better pain relief at all times and at all measurements compared to IM morphine |
| McRae et al.2015 [ | Australia | FICB = 11 vs standard care (IV morphine) = 13 | 15–20 mL 2% lidocaine, weight-dependent | NRS, adverse events | FICB group had a greater reduction in pain than those who received standard care |
| Wennberg et al. 2019 [ | Sweden | FICB = 66 vs placebo (saline) = 61 (adjunctive therapy) | 30 mL 0.2% ropivacaine | VAS | Low-dose FICB improved pain management as a pain-relieving adjuvant to other analgesics |
| Pasquier et al. 2019 [ | Switzerland | FICB = 15 vs placebo (saline) = 15 (adjunctive therapy) | 30 mL 0.5% bupivacaine | NRS (rest/movement), total morphine consumption | Anatomic landmark-based FICB did not help reduce pain after prehospital morphine |
| Godoy Monzón et al. 2010 [ | Argentina | FICB = 62 vs IV NSAIDs (Diclofenac or Ketorolac) = 92 | 0.3 mL/kg 0.25% bupivacaine | VAS | FICB can provide equally effective analgesia as NSAIDs for up to 8 h |
| Ma et al. 2018 [ | China | CFICB = 44 vs oral drugs (tramadol and paracetamol) = 44 | 50 mL 0.4% ropivacaine, 5 mL/h 0.2% ropivacaine continuously | VAS (rest/movement), patients' satisfaction, side effects, length of hospital stay | Patients treated with CFICB received better analgesia both at rest and at movement compared to traditional analgesia |
| Newman et al. 2013 [ | UK | FICB = 56 vs FNB = 51 | 20–30 mL 0.5% levobupivacaine, weight-dependent | VAS, opioid consumption | Patients treated with FNB had better pain control and less morphine requirement |
| Zhou et al. 2019 [ | China | FICB = 77 vs FONB = 77 | 35 mL 0.4% ropivacaine | VAS (rest/exercise), requirement for analgesic drugs, postoperative complications | Both FONB and FICB were effective in acute pain control. FONB performed better in reducing pain and function recovery |
| Cooper et al. 2019 [ | Australia | FICB = 52 vs FNB = 48 | 20 mL 0.5% levobupivacaine | NRS | FICB can provide equivalent analgesia effect as FNB for femur fracture patients |
| Reavley et al. 2015 [ | UK | FICB = 88 vs “3-in-1”block = 90 | 2 mg/kg 0.5% bupivacaine | VAS | FICB was as effective as “3-in-1” block for immediate pain relief |
| Aprato et al. 2018 [ | Italy | FICB = 70 vs IAHI = 50 | 40 mL 0.25% ropivacaine | NRS (rest/movement), additional analgesic drug, adverse events | IAHI provided better pain management and reduced systemic analgesia consumption compared with FICB |
| Wennberg et al. 2019 [ | Sweden | FICB = 65 vs control = 60 | 30 mL 2 mg/mL ropivacaine | Changes of cognitive status | FICB did not affect cognitive status in this study |
|
| |||||
| Application before surgical anesthesia | |||||
| Yun et al. 2009 [ | Korea | FICB = 20 vs IV alfentanil = 20 | 30 mL 0.375% ropivacaine | Time to achieve SA, VAS, quality of patient positioning, patient acceptance | FICB was more efficacious than IV alfentanil with better pain control during positioning and shorter time to achieve SA as well |
| Diakomi et al. 2014 [ | Greece | FICB = 21 vs IV fentanyl = 20 | 40 mL 0.5% ropivacaine | Time needed and quality of position, NRS, postoperative analgesia, morphine consumption, patient satisfaction | Patients who received FICB showed significantly lower pain score, shorter spinal performance time, and better quality of position |
| Madabushi et al. 2016 [ | India | FICB = 30 vs IV fentanyl = 30 | 30 mL 0.375% ropivacaine | VAS, sitting angle, positioning quality, time to perform SA, postoperative analgesic requirement | Patients who received FICB needed less time for SA and had better quality of positioning accompanied by superior analgesia |
| Kacha et al. 2018 [ | India | FICB = 50 vs placebo (normal saline) = 50 | 30 mL 0.25% ropivacaine | VAS, time of positioning SA, total duration of analgesia | FICB effectively provided analgesia during positioning for SA and significantly extended the total duration of analgesia |
|
| |||||
| Postoperative use | |||||
| Temelkovska-Stevanovska et al. 2014 [ | Macedonia | FICB = 30 vs FNB = 30 | 40 mL 0.25% bupivacaine | VDS (rest/movement), additional analgesia, and duration for the first time, side effects | FNB provided superior postoperative pain relief versus FICB, and lower amount of supplemental analgesia |
| Deniz et al. 2014 [ | Turkey | FICB = 20 vs “3-in-1” block = 20 vs control = 20 | 30 mL 0.25% bupivacaine | VAS, opioid consumption, adverse effects, and cortisol and ACTH levels | Both FICB and “3-in-1” block can bring superior analgesia and reduction in opioid consumption. The two blocks also showed a suppression of stress hormones |
| Bang et al. 2016 [ | Korea | FICB = 11 vs. Non-FICB = 11 | 40 mL 0.2% ropivacaine | Postoperative VAS scores, opioid consumption, and adverse events | The FICB had a significant opioid-sparing effect in the first 24 hours after hemiarthroplasty |
| Mostafa et al. 2018 [ | Egypt | FICA = 30 vs. IV fentanyl = 30 | 35 mL 0.125% levobupivacaine + PC-FICA | Postoperative VAS scores, additional analgesia requirement, and total additional analgesia assumption | PC-FICA provided a better quality of analgesia and decreased postoperative rescue analgesic requirement without increased side effects compared to PCA IV fentanyl |
| Yamamoto et al. 2019 [ | Japan | FICB = 25 vs IV acetaminophen = 28 | 40 mL 0.25% levobupivacaine | VAS (rest/movement), total number of rescue analgesics required, incidence of delirium | Patients treated with FICB received better pain control compared to IV NSAIDs without increasing the complication rate |
| Thompson et al. 2020 [ | America | FICB = 23 vs control = 24 | 30 mL 0.25% ropivacaine | Pain medication consumption, functional recovery, patient satisfaction | FICB significantly decreased postoperative consumption of morphine for breakthrough pain while increasing patient satisfaction |
| Schulte et al. 2020 [ | USA | FICB = 57 vs control = 40 | 45 to 60 mL 0.375% ropivacaine | VAS, MME, postoperative ambulatory distance | A single perioperative FIB for patients with hip fractures undergoing surgery may decrease opioid consumption and increase the likelihood that a patient is discharged home |
| Diakomi et al. 2020 [ | Greece | FICB = 91 vs sham FICB = 91 | 40 mL 0.5% ropivacaine | Incidence, intensity, and severity of CPSP at 3 and 6 months after hip fracture surgery | FICB in the perioperative setting may reduce the incidence, intensity, and severity of CPSP at 3 and 6 months after hip fracture surgery, providing safe and effective postoperative analgesia |
|
| |||||
| Other benefits of FICB | |||||
| Mouzopoulos et al. 2009 [ | Greece | FICB = 102 vs placebo (water for injection) = 105 | 0.25 mg dose of 0.3 mL/kg bupivacaine | Perioperative delirium, mean duration of delirium | Severity and incidence of delirium were significantly lower in intermediate-risk patients treated with FICB, along with shorter mean duration of delirium |
| Nie et al. 2015 [ | China | CFICB = 51 vs PCIA (IV fentanyl) = 53 | 20–30 mL 0.5% ropivacaine, 0.1 mL/kg/h 0.25% ropivacaine continuously | Postoperative pain and complications (delirium, nausea and vomiting, and pruritus) | FICB showed a stronger effect on reducing postoperative nausea and vomiting, and pruritus, but with a higher incidence of developing delirium |
| Hao et al. 2019 [ | China | CFICB = 44 vs placebo (normal saline) = 46 | 30 mL 0.45% ropivacaine, 6 mL/h 0.25% ropivacaine continuously | Postoperative delirium, change in preoperative and postoperative pain scores, opioid consumption | The incidence of post-op delirium was lower for patients who received CFICB |
RCTs: randomized controlled trials; FICB: fascia iliaca compartment block; VRS: verbal rating scale; IM: intramuscular; IV: intravenous; NRS: numerical rating scale; VAS: visual analogue scale; NSAIDs: non-steroidal anti-inflammatory drugs; CFICB: continuous fascia iliaca compartment block; FNB: femoral nerve block; FONB: femoral obturator nerve block; IAHI: intra-articular hip injection; SA: spinal anesthesia; VDS: verbal descriptive scale; ACTH: adrenocorticotropic hormone; PCIA: patient-controlled intravenous analgesia; FICA: fascia iliaca compartment analgesia; PC-FICA:: patient-controlled fascia iliaca compartment analgesia; MME: morphine milligram equivalents; CPSP: chronic postsurgical pain. Protocol: a continuous basal infusion of 4 mL/h levobupivacaine 0.125% and demand boluses of 2 ml with a lockout interval of 15 min.